Premalignant hematological system disease

This pilot study tests whether the drug ropeginterferon is safe and feasible for 12 people with a JAK2 mutation and high-risk features who do not yet have a blood cancer. Participants receive an injection every 4 weeks and are monitored closely. The goal is to see if this approac…

This early-stage study tests a new treatment using special immune cells (CAR-T cells) designed to reduce harmful antibodies that can prevent or damage bone marrow transplants. About 18 people with blood diseases who have these antibodies will receive the cells in increasing doses…

This study tests a low-dose oral drug (decitabine with tetrahydrouridine) in 80 adults aged 60–85 who have a high-risk blood condition called CCUS, which often leads to blood cancer. The drug aims to reduce harmful mutations in blood cells and restore normal blood production with…

This study tests whether starting tube feeding right after a stem cell transplant can reduce severe gut graft-versus-host disease (GVHD) in people with blood cancers or disorders. About 112 participants will be randomly assigned to either standard care or early tube feeding. The …

This study investigates whether a condition called clonal hematopoiesis of indeterminate potential (CHIP), which is an age-related change in blood cells, is linked to more severe heart damage in people who have had a major heart attack (STEMI). Researchers will test blood samples…

This study is a registry that will collect medical information and blood samples from 500 adults with myelodysplastic syndromes (MDS) and related conditions. The goal is to learn more about how these diseases develop and progress over time. Participants will not receive any exper…

This study will follow 5,000 adults with immune system problems to see if certain blood cell mutations (called clonal hematopoiesis) are linked to their condition. Researchers will track new cases of immune-related diseases over time. No treatments or drugs are tested—this is pur…